Calculating Glucagon‐Like Pepide‐1 Receptor Agonist‐Associated Medullary Thyroid Cancer Risk: A Novel Integration of the Surveillance, Epidemiology and End Results Cancer Registry and the FDA Adverse Event Reporting System
Head & Neck · 2026
DOI: 10.1002/hed.70286 ↗Kurz gefasst
Fachartikel in der Zeitschrift Head & Neck, 2026. Verfasst von Stella J D'Arcy und 11 weiteren Autor:innen. Beteiligte Einrichtung: Northwell, New Hyde Park, New York, USA. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Carcinoma, Neuroendocrine, Glucagon-Like Peptide-1 Receptor Agonists, Adverse Drug Reaction Reporting Systems. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Background
GLP‐1 receptor agonists carry an FDA boxed warning for medullary thyroid carcinoma (MTC) risk, though conflicting clinical evidence has generated tremendous controversy regarding this association.
Methods
We analyzed SEER and FAERS databases to compare MTC and papillary thyroid cancer (PTC) reporting proportions (RP) between the general population and GLP‐1RA users ( n = 109 168), controlling for surveillance bias by comparing against other endocrine and non‐endocrine drugs. Negative binomial regression was used to estimate the incidence rate ratios (IRR) in the FAERS dataset among patients with reported AEs.
Results
The 10‐year mean MTC RP in SEER/FAERS was 0.0002%/0.0014%, while PTC was 0.012%/0.0087%. Strikingly, GLP‐1RA users showed increased RPs as compared to the total FAERS RPs: MTC 0.071% (50.7‐fold increase) and PTC 0.164% (18.9‐fold increase) with significantly elevated IRRs ( p = 0.0001) compared to reference groups.
Conclusion
GLP‐1RAs showed a higher RP for MTC compared to other drug classes, warranting prospective studies to investigate further.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Northwell, New Hyde Park, New York, USA.
- Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York, USA.
- Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.
- Biostatistics Unit, Office of Academic Affairs, New Hyde Park, New York, USA.
- Department of Otolaryngology, Long Island Jewish Medical Center, New Hyde Park, New York, USA.
- Department of Medicine, Long Island Jewish Medical Center, New Hyde Park, New York, USA.
ORCID-Profile: Sophia L Kennedy, Brett Miles, Rajarsi Mandal
Zitieren
APA
D'Arcy, S. J., Kennedy, S. L., Thomas, J. A., Rahman, H., Sison, C., Kamdar, D., Periera, L., Miles, B., Frank, D., Seetharamu, N., Taneja, C., & Mandal, R. (2026). Calculating Glucagon‐Like Pepide‐1 Receptor Agonist‐Associated Medullary Thyroid Cancer Risk: A Novel Integration of the Surveillance, Epidemiology and End Results Cancer Registry and the FDA Adverse Event Reporting System. Head & Neck. https://doi.org/10.1002/hed.70286
Vancouver
D'Arcy SJ, Kennedy SL, Thomas JA, Rahman H, Sison C, Kamdar D, et al. Calculating Glucagon‐Like Pepide‐1 Receptor Agonist‐Associated Medullary Thyroid Cancer Risk: A Novel Integration of the Surveillance, Epidemiology and End Results Cancer Registry and the FDA Adverse Event Reporting System. Head & Neck. 2026. doi:10.1002/hed.70286
BibTeX
@article{DArcy2026,
author = {D'Arcy, Stella J and Kennedy, Sophia L and Thomas, Jerin A and Rahman, Husneara and Sison, Cristina and Kamdar, Dev and Periera, Lucio and Miles, Brett and Frank, Douglas and Seetharamu, Nagashree and Taneja, Charit and Mandal, Rajarsi},
title = {Calculating Glucagon‐Like Pepide‐1 Receptor Agonist‐Associated Medullary Thyroid Cancer Risk: A Novel Integration of the Surveillance, Epidemiology and End Results Cancer Registry and the FDA Adverse Event Reporting System},
journal = {Head & Neck},
year = {2026},
doi = {10.1002/hed.70286}
}
EUVIMED